MARKET

AKRO

AKRO

Akero Therapeutics
NASDAQ
54.55
-0.08
-0.15%
After Hours: 54.55 0 0.00% 17:01 12/05 EST
OPEN
54.65
PREV CLOSE
54.63
HIGH
54.65
LOW
54.30
VOLUME
4.68M
TURNOVER
--
52 WEEK HIGH
58.40
52 WEEK LOW
21.34
MARKET CAP
4.49B
P/E (TTM)
-14.5529
1D
5D
1M
3M
1Y
5Y
1D
GERMANY'S CARTEL OFFICE SAYS IT APPROVED ACQUISITION OF AKERO THERAPEUTICS BY NOVO NORDISK
Reuters · 1d ago
Akero Therapeutics Shareholders Approve Novo Nordisk Merger
TipRanks · 2d ago
Akero Therapeutics Shareholders Approved Proposed Takeover By Novo Nordisk
Benzinga · 2d ago
AKERO THERAPEUTICS INC - STOCKHOLDERS APPROVE ACQUISITION BY NOVO NORDISK - SEC FILING
Reuters · 2d ago
Akero Therapeutics Inc. Held Special Shareholder Meeting
Reuters · 2d ago
NVO,LLY: Shares Drop as Word Health Organization Calls for Cheaper Versions of Weight-Loss Drugs
TipRanks · 4d ago
Weekly Report: what happened at AKRO last week (1124-1128)?
Weekly Report · 4d ago
Weekly Report: what happened at AKRO last week (1117-1121)?
Weekly Report · 11/24 09:05
More
About AKRO
Akero Therapeutics, Inc. is a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, including metabolic dysfunction-associated steatohepatitis (MASH). Efruxifermin (EFX), its lead product candidate for MASH, is being evaluated in three ongoing Phase 3 studies: SYNCHRONY Outcomes in patients with compensated cirrhosis (F4) due to MASH, SYNCHRONY Histology in patients with pre-cirrhotic (F2-F3 fibrosis) MASH, and SYNCHRONY Real-World in patients with MASH (F1-F4). The Phase 3 SYNCHRONY program builds on the results of two Phase 2b clinical trials, the HARMONY study in patients with pre-cirrhotic MASH and the SYMMETRY study in patients with compensated cirrhosis due to MASH. EFX is an analog of fibroblast growth factor 21 (FGF21), which is an endogenously expressed hormone that protects against cellular stress and regulates metabolism of lipids, carbohydrates and proteins throughout the body.

Webull offers Akero Therapeutics Inc stock information, including NASDAQ: AKRO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, AKRO stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading AKRO stock methods without spending real money on the virtual paper trading platform.